In this episode, David Flores engages in a conversation with Brett Waters, Esq., the Co-Founder and Executive Director of Reason for Hope, to explore policy and legal reforms aimed at realizing safe, ethical, and affordable access to psychedelic-assisted therapy.
Entheon Biomedical CEO Timothy Ko (CSE: ENBI) (OTC: ENTBF) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction with DMT.
Entheon Biomedical is pioneering a leading-edge addiction recovery solution that harnesses and optimizes the therapeutic potential of the DMT molecule. Entheon exists to invert the addiction-recovery ratio, turning the ‘untreatable case’ and ‘lost cause’ from the norm to the exception.
Entheon Biomedical is developing a DMT-assisted therapeutic protocol that will be specifically tailored to address the core mechanisms underlying drug-seeking and using behavior. Our chief aim is to provide an effective and scalable therapeutic protocol that will serve as a vital resource for those afflicted with a substance-use disorder, and who are wanting to reclaim their lives.
Entheon’s DMT clinical trial later this year will put it in direct competition with MindMed (MMED /MMEDF), who is also planning on launching a DMT clinical trial later this year.
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
For any potential collaborations, please reach us at: thepsychedelicinvestor@gmail.com
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
The Psychedelic Investor was compensated $1,000 by Future Money Trends for the making of this video on Entheon Biomedical. James (The Psychedelic Investor) does not own a position in Entheon Biomedical and will not open one for at least 30 days after publication of this video.
https://entheonbiomedical.com/
CSE: ENBI | OTCQB: ENTBF
This video was conducted on behalf of Entheon Biomedical, and was funded by Gold Standard Media LLC. For our full disclaimer, please visit: https://www.goldstandardir.com/entheon-biomedical-disclaimer-85/
#EntheonBiomedical #Entheon #PsychedelicStocks
Hey guys! Here is an Update and response to our easily most controversial video “MindMed (MMED) Suicide Headaches trial VANISHES from Website ( What Happened?)”. We got a response from MindMed while also receiving some backlash from the MindMed investors community that will be addressed. Hope you guys find some value in this video. I appreciate you guys. LOOVE all comments and criticisms. Caio!
P.S. S/O to Magic Shrooms who also contributed by commenting that he “received a reply from MMED concerning about the cluster headaches trial. they said that there has been no changes in regard to their on-going trial using LSD for suicide headaches!”
Just to let you know, we temporarily (perhaps permanently?) have removed the first video, while we discuss how to move forward.
Subscribe to our channel to get the latest updates on Psychedelic Stocks. Follow the MMED stock and other companies like it.
Let us know in the comments what you think about the new way we edited our video? Do you like it more than how we edited them previously?
🎵 Music: www.bensound.com
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
#MindMed #mmed #mindmedstock #psychedelicstocks #mmedf
Wesana Health’s Dr. ABID NAZEER – The Parallels Between Brain…
In this episode, Dennis Walker speaks with Victor Mifsud about how a few MDMA experiences helped him have a temporary remission of his retinitis pigmentosa, a disease which has caused him to be legally blind.
![MAPS Phase 3 MDMA To Treat PTSD Trial Results: WOW [GREAT News For NUMI, MindMed, MYCO & Atai ]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-72-600x338.jpeg)
MAPS Phase 3 MDMA To Treat PTSD Trial Results Released [ GREAT NEWS For NUMI, MindMed, MYCO & Atai ]
Breaking NEWS: 67% of participants in a recent MAPS sponsored Phase III clinical trial focused on MDMA- assisted therapy no longer qualified for a diagnosis of PTSD, compared with 32% in the placebo group. Also, 88% of participants receiving psychedelic therapy experiences a clinically significant reduction in symptoms of PTSD.
Also, there were 0 cases of serious adverse side effects in the MDMA group.
So which companies will be the largest benefactors of these results?
Numinus Wellness (NUMI / LKYSF ): working in conjunction with MAPS in Canada to conduct a compassionate access trial to those with PTSD. The trial is either already recruiting patients, or is set to do so imminently
2.MindMed ( MMED / MNMD / MMQ) is also working with MDMA, and has recently completely a study on personalized dosing of MDMA. MindMed also has a Phase I trial looking at the effects of combining LSD with MDMA.
3. Atai life sciences is in the preclinical stages of using an MDMA derivative to treat PTSD, through their subsidiary EmpathBio.
4. Mydecine has a compound called MYCO-002, which is similar to MDMA, which they hope to start using in clinical trials soon.
5. Awakn Life Sciences, a private company, also will have a Phase II study looking at treating alcohol use disorder with MDMA.
Link to the article in question: https://www.nytimes.com/2021/05/03/health/mdma-approval.html?fbclid=IwAR3xMWgnKryfZnzWqB7mJ9GrkVuoQE79yC-kVEXJzOyF4n7JEcHOuobw7jQ#click=https://t.co/GVhm9i2wm3
Link to MindMed ( MMED / MNMD/ MMQ ) : https://mindmed.co/
Link to MYDECINE ( MYCO / MYCOF ): https://www.mydecine.com/
Link to Numinus (NUMI): https://numinus.ca/
Link to Atai Life Sceinces : https://www.atai.life/
Link to Awakn Life sciences: https://www.newsfilecorp.com/company/7226/Awakn-Life-Sciences-Inc.
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor
Clinical trials :
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#MindMed #PsychedelicStocks #NUMIStock
Chris works alongside companies to develop plant-based food and medicinal products, helping turn them into market successes. He has conducted medicinal plant research and sustainable botanical sourcing in over 45 countries, and has been featured on a number of platforms such as The New York Times, The Dr. Oz Show, Business Insider, CNN, VICE, and much more.
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.
